Rare diseases on the political - and industry - agenda
This article was originally published in SRA
The treatment of rare diseases is once again rising up the political agenda. In the UK, the All-Party Parliamentary Group for Muscular Dystrophy has just warned that the recent decision to merge cash previously reserved for treating rare diseases into the overall budget for NHS services in England could result in rare conditions having to compete with more ordinary conditions for funding. This in turn could result in it becoming more difficult for patients to gain access to newer, more effective but more expensive treatments.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.